CLLS - CONSENSUS CO - Cellectis S.A.

The linear price action on the Cellectis S.A. (CLLS) chart shows a current level of 4.99. Cellectis S.A. acts as an innovator in gene modification for the development of allogeneic CAR-T therapies. Business revenues are based on licensing fees from global pharma behemoths for access to its technologies. Despite the concentration of development within the oncology sphere, binary risks are mitigated by substantial grants and partnerships.

This indicator represents a weighted average fair value assessment of the asset over a one-year horizon, aggregating expectations from leading investment houses to determine the potential for price growth. By analyzing the analysts' consensus price target, investors can gauge market optimism regarding the success of Cellectis S.A. (CLLS) in the field of TALEN genome editing and the effectiveness of its strategic alliances with pharmaceutical behemoths.